Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Cyxone: Our Q1 Comment

EL

FT

Ethel Luvall

Fredrik Thor

Redeye comments on Cyxone’s Q1 report and potential impact on the new strategy. We also adjust our base case to reflect our assumption that the company needs additional funding to finalize the phase IIb trial with Rabeximod.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers